Anti-Galectin-9 Antibody Combination Therapy for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for solid tumors, particularly pancreatic ductal adenocarcinoma, are limited by the immune suppressive tumor microenvironment mediated by Galectin-9, which hampers effective anti-tumor immune responses.
Innovation Solution
The use of a synergistic combination therapy involving an anti-Galectin-9 antibody, such as G9.2-17, in conjunction with chemotherapeutics like gemcitabine and paclitaxel, to disrupt Galectin-9's interaction with immune receptors, thereby enhancing anti-tumor immune responses and inhibiting tumor progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Galectin-9 is used to modulate immune response, then immune suppression is enhanced, but anti-tumor immune response is inhibited
Solution Approach 1:
The patent converts the harmful immune suppression effect of Galectin-9 into a beneficial anti-tumor response by using anti-Galectin-9 antibodies to block its interaction with TIM-3 and Dectin-1 receptors. This prevents Galectin-9 from suppressing anti-tumor immunity while maintaining or enhancing its ability to modulate immune responses favorably against cancer.
Solution Approach 2:
The patent introduces anti-Galectin-9 antibodies as intermediary molecules that mediate between Galectin-9 and its receptors (TIM-3, Dectin-1). These antibodies bind to Galectin-9 and prevent it from interacting with immune cell receptors, thereby controlling the immune suppression effect while allowing therapeutic benefits.
2Reliability
If combination therapy with anti-Galectin-9 antibody and chemotherapeutics is used, then anti-tumor efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two distinct treatment modalities into a unified combination therapy: anti-Galectin-9 antibody therapy (immunotherapy) and conventional chemotherapeutics (gemcitabine, paclitaxel). This combination synergistically enhances anti-tumor efficacy by targeting both immune suppression and direct tumor cell killing, while the patent provides specific dosing schedules and administration protocols to manage the complexity of the combined treatment.
Data Source
AI summary
Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.